Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P643 Development of quantitative ultrasonographic activity score in ileal Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

M. Livne Margolin1, M. Amitai2, E. Klung2, B. Ungar1, R. Eliakim1, S. Ben-Horin1, D. Carter1, U. Kopylov1

1Department of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel, 2Department of Diagnostic Imaging, Sheba Medical Center, Ramat Gan, Israel

P644 Post-operative Crohn’s disease recurrence in Glasgow: How common is it and does deprivation matter?

ECCO'20 Vienna

Year: 2020
Authors:

E. Brownson1, S. Shields1, M.H. Derakhshan1, J. Macdonald1, G. Nicholson2, J.P. Seenan1

1Queen Elizabeth University Hospital, Department of Gastroenterology, Glasgow, UK, 2Queen Elizabeth University Hospital, Department of Surgery, Glasgow, UK

P645 Adalimumab drug monitoring is superior to empirical treatment adjustment in inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

P. CURRAIS1, S. Fernandes2, S. Bernardo2, L. Correia2, A.R. Gonçalves2, C. Baldaia2, P. Moura Santos2, A. Valente2, R. Tato Marinho2

1Instituto Português de Oncologia de Lisboa, Gastrenterologia, Lisboa, Portugal, 2Hospital de Santa Maria, Gastrenterologia, Lisboa, Portugal

P646 Utilisation of indocyanine green fluorescence imaging for Crohn’s disease following intestinal resection

ECCO'20 Vienna

Year: 2020
Authors:

Y. Duan, Y. Li

Shanghai Ninth People’s Hospital- Shanghai Jiao Tong University School of Medicine Department of general surgery, Shanghai Ninth People’s Hospital- Shanghai Jiao Tong University School of Medicine, Department of general surgery, shanghai, China

P647 Post-marketing evaluation of reported adverse events of a multi-strain probiotic product confirms that change in manufacturing site had no impact on safety profile

ECCO'20 Vienna

Year: 2020
Authors:

V. Panetta1, I. Simonelli1, A. Bacchieri2, S. Papetti3, E. De Stefani3, S. Colombo4

1L’altrastatistica Srl, for GB Pharma Services and Consulting S.r.l, Rome, Italy, 2Clinical Research and Development Consultants, S.r.l., Sesto Fiorentino, Italy, 3GB Pharma Services and Consulting, S.r.l., Pavia, Italy, 4Beingpharma, S.r.l, Milano, Italy

P648 Efficacy including rapid response and safety of tofacitinib in Japanese patients with ulcerative colitis: A preliminary investigation in a specialised IBD centre

ECCO'20 Vienna

Year: 2020
Authors:

K. WatanabeAssistant Professor1, M. Kawai2, R. Koshiba2, K. Fujimoto2, K. Kojima2, K. Kaku2, N. Kinoshita2, T. Sato1, K. Kamikozuru2, Y. Yokoyama2, T. Miyazaki2, N. Hida2, S. Nakamura2

1Hyogo College of Medicine, Department of Intestinal Inflammation Research, Hyogo, Japan, 2Hyogo College of Medicine, Division of Internal Medicine- Department of Inflammatory Bowel Disease, Hyogo, Japan

P649 Dietary habits in patients with inactive Crohn’s disease: Results of a controlled study

ECCO'20 Vienna

Year: 2020
Authors:

N. Ben Mustapha, H. Ben Youssef, A. Labidi, M. Hafi, M. Fekih, M. Serghini, J. Boubaker

La Rabta Hospital Tunis El Manar University, Department of Gastroenterology A, Tunis, Tunisia

P650 Outcomes of endoscopic balloon dilation for luminal strictures in Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

R. Sarraj, M. Martinho, F. Bravo, E. Benz, P. Juillerat

Inselspital Bern, Gastroenterology- Clinical for Visceral Surgery and Medicine, Bern, Switzerland

P651 Does ambient temperature alter faecal calprotectin levels?

ECCO'20 Vienna

Year: 2020
Authors:

S. Cauchi1, J. Schembri2, M. Muscat2, P. Ellul2

1Mater Dei Hospital- Malta, Department of Medicine, Kirkop, Malta, 2Mater Dei Hospital- Malta, Department of Gastroenterology, Msida, Malta

P652 Underweight patients with Crohn’s disease and without vitamin D supplementation are at high risk of vitamin D deficiency

ECCO'20 Vienna

Year: 2020
Authors:

D. Vranesic Bender1, V. Domislović2, M. Brinar2,3, D. Ljubas Kelečić1, I. Karas1, M. Novosel3, M. Matašin3, Ž. Krznarić1,2,3

1Unit for Clinical Nutrition, Department of Gastroenterology and Hepatology, Zagreb, Croatia, 2Clinical Hospital Centre Zagreb, Department of Gastroenterology and Hepatology, Zagreb, Croatia, 3Zagreb School of Medicine, University of Zagreb, Zagreb, Croatia

P653 Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Updated results of the OCTAVE Open study for tofacitinib 8-week induction non-responders

ECCO'20 Vienna

Year: 2020
Authors:

D.T. Rubin1, M.C. Dubinsky2, S. Danese3, R. Saad-Hossne4, D. Ponce de Leon5, E. Maller6, N. Lawendy6, K. Kwok7, C. Su6

1Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois, USA, 2Department of Pediatrics and Medicine- Icahn School of Medicine at Mount Sinai, New York, New York, USA, 3IBD Center- Department of Gastroenterology- Humanitas Research Hospital, Rozzano, Milan, Italy, 4IBD Group- Botucatu Medical School- São Paulo State University, São Paulo, Brazil, Brazil, 5Pfizer Inc., Lima, Peru, Peru, 6Pfizer Inc., Collegeville, Pennsylvania, USA, 7Pfizer Inc., New York, New York, USA

P654 Influence of the interval of time between anti-TNF and vedolizumab or ustekinumab in the response to treatment in patients with inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

I. Bastón Rey1, M. Costa1, C. Calviño-Suarez1, V. Mauriz-Barreiro1, D. De la Iglesia1, J. Gonzalez2, R. Ferreiro-Iglesias1, J.E. Dominguez- Munoz1, M. Barreiro-de Acosta1

1University Hospital Santiago De Compostela CHUS, Department of Gastroenterology- IBD Unit, Santiago De Compostela, Spain, 2University Hospital Santiago De Compostela CHUS, Department of Pharmacy, Santiago De Compostela, Spain

P655 Pharmacokinetics of ustekinumab in children and adolescents with moderately to severely active Crohn’s disease: Results from UniStar, a phase 1 study

ECCO'20 Vienna

Year: 2020
Authors:

O. Adedokun1, J. Hyams2, D. Turner3, A. Griffiths4, N. Terry5, L. Padgett5, D. Jacobstein6, C. O’Brien5, J. Rosh7

1Janssen Research and Development- LLC, Clinical Pharmacology, Horsham- PA, USA, 2Connecticut Children’s Medical Center, Pediatrics, Hartford- CT, USA, 3Shaare Zedek Medical Center, Pediatrics, Jerusalem, Israel, 4SickKids Hospital, Pediatrics, Toronto, ON, Canada, 5Janssen Research and Development, LLC, Research and Development, Horsham, PA, USA, 6former employee of Janssen Research and Development, LLC, current employee of Provention Bio, Research and Development, Horsham, PA, USA, 7Goryeb Children’s Hospital/Atlantic Health, Pediatrics, Morristown, NJ, USA

P656 Clinical implications of endoscopic submucosal dissection in management of patients with ulcerative colitis-associated dysplasia

ECCO'20 Vienna

Year: 2020
Authors:

T. Sakurai1, R. Nezu2, A. Okada3, Y. Komeda1, T. Nagai1, S. Masaki1, M. Yamada1, K. Takashima1, H. Kashida1, M. Kudo1

1Kindai University, Department of Gastroenterology, Osaka-Sayama, Japan, 2Nishinomiya Municipal Central Hospital, Surgery, Nishinomiya, Japan, 3Wakakusa Daiichi Hospital, Gastroenterology, Higashi-Osaka, Japan

P657 Evolution of Crohn’s disease progression and surgery rates over 10 years for patients who initiated biologic treatment early compared with late or no biologic initiation

ECCO'20 Vienna

Year: 2020
Authors:

N. Pillai1, M. Dusheiko1, M. Maillard2, P. Michetti2, V. Pittet PhD1, Swiss IBD Cohort Study

1Center for Primary Care and Public Health - University of Lausanne, Epidemiology and Health Services, Lausanne, Switzerland, 2Gastroenterologie La Source-Beaulieu, Centre Crohn et Colite, Lausanne, Switzerland

P658 A pooled analysis of serum phosphate measurements and transient decreased phosphate levels in 45 interventional trials with ferric carboxymaltose

ECCO'20 Vienna

Year: 2020
Authors:

J.M. Stein1, I. Schiefke2, U.M. Göhring3, V. Fabien4, G. Rosano5

1DGD Hospital Frankfurt-Sachsenhausen, Klinik für Gastroenterologie/Onkologie, Frankfurt/Main, Germany, 2Klinikum St. Georg, Department of Gastroenterology, Hepatology, Diabetology and Endocrinology, Leipzig, Germany, 3Vifor Pharma, Clinical Development, Zurich, Switzerland, 4Vifor Pharma, Biometrics, Zurich, Switzerland, 5St George’s Hospitals NHS Trust, Clinical Academic Cardiovascular Group-, London, UK

P659 The impact of total colectomy on the course of extraintestinal manifestations in Swiss IBD cohort study patients

ECCO'20 Vienna

Year: 2020
Authors:

R. Roth1, S. Vavrick2, M. Scharl1, P. Schreiner1, T. Greuter1, J. Zeitz3, E. Safroneeva4, A. Schoepfer5, M.P. Barry6, G. Rogler1, L. Biedermann1, Swiss IBD Cohort Study

1University Hospital Zurich, Gastroenterology and Hepatology, Zuerich, Switzerland, 2Private Practice, Center for Gastroenterology and Hepatology, Zurich, Switzerland, 3Clinic Hirslanden- Zurich- Switzerland, Center of Gastroenterology, Zurich, Switzerland, 4University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, 5Centre Hospitalier Universitaire Vaudois CHUV and University of Lausanne, Division of Gastroenterology and Hepatology, Lausanne, Switzerland, 6Center for Primary Care and Public Health Unisanté – University of Lausanne, Institute of Social and Preventive Medicine IUMSP, Lausanne, Switzerland

P660 Evaluating the effectiveness of disease assessment at 2 weeks following a course of oral steroids: Does early intervention affect outcomes?

ECCO'20 Vienna

Year: 2020
Authors:

J. Slater, A. ALGIEDER, J. Jones, B. Bates, S. De Silva

The Dudley Group NHS Foundation Trust, Gastroenterology, Dudley, UK

P661 Post-operative prophylaxis with anti-TNF in patients with Crohn’s disease who are anti-TNF experienced is associated with higher rates of prophylaxis failure

ECCO'20 Vienna

Year: 2020
Authors:

M. Aharoni Golan1,2, J. Ollech1,2, I. Avni Biron1,2, Y. Broitman1,2, Y. Snir1,2, H. Banai Eran1,2, H. Leibovitzh1,2, I. Goren1,2, N. Wasserberg2,3, I. Dotan1,2, H. Yanai1,2

1Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel, 2Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel, 3Rabin Medical Center, Department of Surgery B, Petah Tikva, Israel

P662 Efficacy and safety of tofacitinib in patients with moderate-to-severe ulcerative colitis: A real-world retrospective study

ECCO'20 Vienna

Year: 2020
Authors:

N. Yoshimura, Soh. Okano, Minako. Sako, Masakazu. Takazoe

Tokyo Yamate Medical Center, Department of Internal Medicine-Division of IBD, Tokyo, Japan